KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Sells 174,645 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the firm’s stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $16.95, for a total transaction of $2,960,232.75. Following the sale, the insider owned 5,129,340 shares of the company’s stock, valued at $86,942,313. This trade represents a 3.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Thursday, March 26th, Venrock Healthcare Capital Par sold 39,986 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $18.28, for a total transaction of $730,944.08.

KalVista Pharmaceuticals Stock Up 2.0%

KalVista Pharmaceuticals stock opened at $19.33 on Friday. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.23 and a twelve month high of $19.95. The firm has a 50 day moving average price of $16.04 and a 200-day moving average price of $14.46. The company has a market capitalization of $990.08 million, a P/E ratio of -4.89 and a beta of -0.35. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18.

Institutional Trading of KalVista Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its holdings in KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at $55,000. Wolverine Asset Management LLC bought a new stake in KalVista Pharmaceuticals during the 3rd quarter valued at $57,000. KLP Kapitalforvaltning AS purchased a new stake in shares of KalVista Pharmaceuticals during the third quarter worth $63,000. Finally, Truvestments Capital LLC lifted its position in shares of KalVista Pharmaceuticals by 253.8% during the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after acquiring an additional 3,360 shares in the last quarter.

Trending Headlines about KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Unusual bullish options flow: traders bought 5,072 call options (≈569% above the average of 758), suggesting speculative or hedged bullish positioning that can amplify near-term upside interest in the shares.
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a “buy” rating — a large upside vs. the current level that often attracts renewed investor attention and buying. Stifel price target raise
• Positive Sentiment: Needham & Company increased its target to $36 and kept a “buy” rating, reinforcing analyst conviction from multiple firms. Needham target raise
• Positive Sentiment: EKTERLY commercial launch showing strong initial revenue: KalVista reported $49.1M in EKTERLY revenue during an eight-month transition period — a material commercial proof point that supports revenue growth expectations. EKTERLY revenue report
• Positive Sentiment: Stock hit a new 52-week high after analyst upgrades and increased coverage, a technical signal that can attract momentum buyers. 52-week high / analyst upgrade
• Neutral Sentiment: Recent earnings materials (Q1 2025 call summary and transcript) have been published — useful for revisiting guidance and management commentary but the market reaction depends on details and forward guidance. Q1 2025 earnings call summary
• Negative Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 (still a “market outperform”), a modest downtick in one analyst’s view that could temper upside expectations if other firms follow. Citizens Jmp target change

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on KALV. Citizens Jmp reduced their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a report on Thursday. Stifel Nicolaus boosted their target price on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Needham & Company LLC increased their price target on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $32.60.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.